Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBC-102 in Adult LAL Deficiency
NCT01307098Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2011
- Primary completion
- Jan 2012
- Modality
- Replacement Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of sebelipase alfa in lysosomal acid lipase deficiency (LALD), sponsored by Alexion Pharmaceuticals. Started Apr 2011; status: completed.
02
Drugs
sebelipase alfa
03
Conditions
lysosomal acid lipase deficiency (LALD)
Beyond the preview
Go deeper on NCT01307098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01307098.